Semax news
Regulator decisions, trial results and approvals involving Semax, newest first. Each report is dated and cites the official record.
FDA advisory committee reviews BPC-157, TB-500 and five other peptides for compounding
On 23 and 24 July 2026 the FDA's Pharmacy Compounding Advisory Committee met to consider whether seven peptides, including BPC-157 and TB-500, should be added to the list of bulk substances US pharmacies may compound with. FDA's own briefing papers proposed that none of them be added. The committee's advice is not binding, and FDA has not announced a decision.
Medsafe warns New Zealanders that unapproved peptides are illegal to import, sell or use
On 21 May 2026 Medsafe, New Zealand's medicines regulator, issued a consumer advisory on unapproved peptide products and SARMs, naming BPC-157, retatrutide, TB-500 and others. It said many of these products are prescription medicines, that "for research purposes only" labels have no legal effect, and that Medsafe continues to seize them.